NCBP2

Across TCGA pan-cancer cohorts, NCBP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCBP2 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NCBP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCBP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where NCBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LUAD	OS	Tertile	II,III,IV	0.548	0.946	.014	6	view →
CCRCC	DFS	Quartile	All	0.683	0.946	.019	6	view →
HNSC	DFS	Quartile	IV	0.456	0.772	.032	3	view →
GBM	OS	Tertile	All	0.487	0.247	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCBP2–PDAC (DFS)

Open the PDAC breakdown →